Blood Tests for Alzheimer's Are Here New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments--such as monoclonal antibodies--sooner. Last month, The US Food and Drug Administration approved a new blood test for assisting the diagnosis of Alzheimer's disease. Tau is one of two proteins, the other being amyloid, that become malformed and accumulate in the brains of patients with certain types of dementia. It is believed that the buildup of these proteins interferes with the communication of brain cells, leading to these patients' symptoms. The test had already received authorization in July for marketing in Europe and is thus the first early screening system for Alzheimer's for use in primary care settings approved in the planet's two major pharmaceutical markets.

COLLEGE STATION, TX / ACCESSWIRE / June 7, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it intends to execute to meet the Company's objective of producing a therapeutic cure for HIV as well as a planned protocol to address existing and future pandemics. This protocol has been defined as a result of the Company's collaboration with Intel Corporation in the field of applying computer analysis (Artificial Intelligence - A.I.) to accelerate health care discoveries and development. This collaboration includes exploring the interaction of monoclonal antibodies with viruses in 3-dimensional matrices. This opens new innovative pathways for drug discovery and development. The Company is actively exploring biotech partnerships, in the same way the Company is working with Intel Corporation, to advance and provide effective therapies and cures for existing and new viral illnesses. In combination with the Company's patented and clinically tested anti-HIV peptide ITV-1, the Company proposes a collaboration to fully implement the following protocol for developing and deploying therapeutics to address existing and future pandemics.

Enzolytics, Inc. (ENZC) is making a powerful move up the charts in recent days since a brief dip below the $0.10 mark. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. ENZC has partnered with Intel to publish a white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlighting Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.

As artificial intelligence becomes a standard laboratory tool, scientists are quickly discovering both the promise and perils of algorithmically driven research. Artificial intelligence (AI) is cropping up everywhere these days, according to major news sources that are themselves increasingly driven by computer algorithms. Marketers use AI to target advertisements, engineers use it to anticipate device failures, and AI-driven social media platforms wield outsize influence on everything from fashion to politics. While all types of AI--also called machine learning--entail programming a computer to learn from examples and make inferences, practitioners distinguish different forms of it. Within the broader field of AI, a subset of strategies employ artificial neural networks. These mimic biological brains, with elements of a program connecting to each other like neurons.